EVFM vs. SBFM, SPRC, EVLO, HSTO, BLPH, LSDI, CMRA, GRI, ADTX, and SXTC
Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Sunshine Biopharma (SBFM), SciSparc (SPRC), Evelo Biosciences (EVLO), Histogen (HSTO), Bellerophon Therapeutics (BLPH), Lucy Scientific Discovery (LSDI), Comera Life Sciences (CMRA), GRI Bio (GRI), Aditxt (ADTX), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical preparations" industry.
Evofem Biosciences (NASDAQ:EVFM) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.
Evofem Biosciences has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
In the previous week, Evofem Biosciences had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 3 mentions for Evofem Biosciences and 2 mentions for Sunshine Biopharma. Evofem Biosciences' average media sentiment score of 0.16 beat Sunshine Biopharma's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.
Sunshine Biopharma has a consensus target price of $260.00, indicating a potential upside of 27,856.99%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Evofem Biosciences.
Evofem Biosciences has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Evofem Biosciences received 261 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 69.50% of users gave Evofem Biosciences an outperform vote.
Evofem Biosciences has a net margin of 315.54% compared to Sunshine Biopharma's net margin of -18.70%. Sunshine Biopharma's return on equity of -21.03% beat Evofem Biosciences' return on equity.
0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by insiders. Comparatively, 4.1% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Evofem Biosciences and Sunshine Biopharma tied by winning 9 of the 18 factors compared between the two stocks.
Get Evofem Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evofem Biosciences Competitors List
Related Companies and Tools
